Eurofins’ empowerDX launches PFAS Exposure™ in the U.S, the First At-Home Blood Test to Detect and Measure 40+ PFAS Compounds
21 Janvier 2022 - 04:03PM
Business Wire
Today, Eurofins (Paris:ERF) subsidiary empowerDX has launched
PFAS Exposure™ in the United States, the first direct to consumer
at-home test to determine levels of PFAS in a person’s blood and
measure 47 of the PFAS “forever chemical” compounds.
Per- and Polyfluorinated Alkyl Substances (PFAS), such as PFOA
and PFOS, known as “forever chemicals”, characteristically resist
natural breakdown in the environment and human bodies. The US
Centers for Disease Control and Prevention (CDC) reports that
exposure to these chemicals may cause adverse health effects, such
as cancer, thyroid disease, immune suppression, elevated
cholesterol, respiratory disease, and decreased fertility. One
report by the CDC’s National Health and Nutrition Examination
Survey (NHANES) found PFAS in the blood of 97% of Americans.
The identification of PFAS through blood testing is a
significant milestone. PFAS Exposure™, developed by Eurofins
Environment Testing companies and their research partners, and
being launched in the U.S by empowerDX, is a self-administered
sampling kit, which is the first of its kind and uses a simple
finger prick. To date, testing for PFAS in blood has relied on
serum as an estimation for whole blood and required a blood draw
conducted by a healthcare practitioner. Eurofins’ PFAS Exposure™
collection kits are an all-in-one solution that include the
essentials for collection and transport, allowing participants to
self-collect samples at home or work, and submit them directly to
the laboratory.
The PFAS Exposure kit is available in the United States through
Eurofins’ at-home health testing business, empowerDX. Kits can be
purchased online for $399 and are shipped directly to the
customer’s home or business.
To learn more, please visit this website.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 55,000 staff across a network
of 900 laboratories in over 50 countries, Eurofins’ companies offer
a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220121005285/en/
Delia Vallejo ir@eurofins.com
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024